A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

Gastroenterology

Volumn 135, Issue 4, 2008, Pages 1130-1141

  Sandborn, William J ^a   Feagan, Brian G ^b   Fedorak, Richard N ^c   Scherl, Ellen ^d   Fleisher, Mark R ^e   Katz, Seymour ^f   Johanns, Jewel ^g   Blank, Marion ^g   Rutgeerts, Paul ^h  

^a MAYO CLINIC   (United States)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e Borland Groover Clinic   (United States)

^f Long Island Clinical Research Associates   (United States)

^g CENTOCOR INC   (United States)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 23; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG; USTEKINUMAB;

ADULT; ANXIETY DISORDER; ARTICLE; BASAL CELL CARCINOMA; CLINICAL TRIAL; COLON STENOSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROHN DISEASE; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; HISTOPLASMOSIS; HOT FLUSH; HUMAN; INJECTION SITE DISCOMFORT; INJECTION SITE IRRITATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROLITHIASIS; OPPORTUNISTIC INFECTION; PNEUMOTHORAX; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SMALL INTESTINE OBSTRUCTION; SQUAMOUS CELL CARCINOMA; SYNCOPE; TREATMENT RESPONSE; VIRAL GASTROENTERITIS;

EID: 53049091561     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.07.014     Document Type: Article

References (35)

1. Hanauer S.B., and Sandborn W. The Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 96 (2001) 635-643
2. Travis S.P., Stange E.F., Lemann M., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 Suppl 1 (2006) i16-i35
3. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337 (1997) 1029-1035
4. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
5. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC I trial. Gastroenterology 130 (2006) 323-333
6. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007) 52-65
7. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 (2007) 228-238
8. Schreiber S., Khaliq-Kareemi M., Lawrance I., et al. Certolizumab pegol maintenance therapy for Crohn's disease. N Engl J Med 357 (2007) 239-250
9. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
10. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 (2007) 829-838
11. Peluso I., Pallone F., and Monteleone G. Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol 12 (2006) 5606-5610
12. Neurath M.F. IL-23: a master regulator in Crohn disease. Nat Med 13 (2007) 26-28
13. Duerr R.H., Taylor K.D., Brant S.R., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314 (2006) 1461-1463
14. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 (2003) 133-146
15. Iwakura Y., and Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 116 (2006) 1218-1222
16. Kastelein R.A., Hunter C.A., and Cua D.J. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 25 (2007) 221-242
17. Neurath M.F., Fuss I., Kelsall B.L., et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182 (1995) 1281-1290
18. Elson C.O., Cong Y., Weaver C.T., et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 132 (2007) 2359-2370
19. Becker C., Dornhoff H., Neufert C., et al. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol 177 (2006) 2760-2764
20. Yen D., Cheung J., Scheerens H., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116 (2006) 1310-1316
21. Mannon P.J., Fuss I.J., Mayer L., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351 (2004) 2069-2079
22. Leonardi C.L., Kimball A.B., Papp K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371 (2008) 1665-1674
23. Papp K.A., Langley R.G., Lobwohl M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371 (2008) 1675-1684
24. Krueger G.G., Langley R.G., Leonardi C., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356 (2007) 580-592
25. Kasper L.H., Everitt D., Leist T.P., et al. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin 22 (2006) 1671-1678
26. Best W.R., Becktel J.M., Singleton J.W., et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976) 439-444
27. Sandborn W.J., Feagan B.G., Hanauer S.B., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122 (2002) 512-530
28. Sandborn W.J., Feagan B.G., Radford-Smith G., et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double-blind, placebo-controlled trial. Gut 53 (2004) 1485-1493
29. Sandborn W.J., Colombel J.F., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353 (2005) 1912-1925
30. Schreiber S., Rutgeerts P., Fedorak R.N., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 (2005) 807-818
31. Su C., Lichtenstein G.R., Krok K., et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 126 (2004) 1257-1269
32. Sands B.E., Steinhart A.H., Lewis J.D., et al. Optimal Crohn's disease activity index (CDAI) response criteria is defined by decrease ≥ 100 points. Gastroenterology 124 Suppl S (2003) A206
33. Rao K.L., Varalakshmi C., Ali A.M., et al. Administration of anti-IL-12 antibody in vivo inhibits rejection of a rat histiocytoma and suppresses cytokine response in a tumour-bearing host. Immunology 92 (1997) 381-387
34. Langowski J.L., Zhang X., Wu L., et al. IL-23 promotes tumour incidence and growth. Nature 442 (2006) 461-465
35. H-17 differentiation: of mice and men. Nat Immunol 8 (2007) 903-905